|
1
|
Longley DB, Harkin DP and Johnston PG:
5-fluorouracil: Mechanisms of action and clinical strategies. Nat
Rev Cancer. 3:330–338. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gustavsson B, Carlsson G, Machover D,
Petrelli N, Roth A, Schmoll HJ, Tveit KM and Gibson F: A review of
the evolution of systemic chemotherapy in the management of
colorectal cancer. Clin Colorectal Cancer. 14:1–10. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Meyerhardt JA and Mayer RJ: Systemic
therapy for colorectal cancer. N Engl J Med. 352:476–487. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tsai HC and Baylin SB: Cancer epigenetics:
Linking basic biology to clinical medicine. Cell Res. 21:502–517.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dokmanovic M, Clarke C and Marks PA:
Histone deacetylase inhibitors: Overview and perspectives. Mol
Cancer Res. 5:981–989. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Prince HM, Bishton MJ and Harrison SJ:
Clinical studies of histone deacetylase inhibitors. Clin Cancer
Res. 15:3958–3969. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Minucci S and Pelicci PG: Histone
deacetylase inhibitors and the promise of epigenetic (and more)
treatments for cancer. Nat Rev Cancer. 6:38–51. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu S, Cheng H, Kwan W, Lubieniecka JM and
Nielsen TO: Histone deacetylase inhibitors induce growth arrest,
apoptosis, and differentiation in clear cell sarcoma models. Mol
Cancer Ther. 7:1751–1761. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bots M and Johnstone RW: Rational
combinations using HDAC inhibitors. Clin Cancer Res. 15:3970–3977.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Iwahashi S, Shimada M, Utsunomiya T,
Morine Y, Imura S, Ikemoto T, Mori H, Hanaoka J and Saito Y:
Histone deacetylase inhibitor enhances the anti-tumor effect of
gemcitabine: A special reference to gene-expression microarray
analysis. Oncol Rep. 26:1057–1062. 2011.PubMed/NCBI
|
|
11
|
Subramaniam D, Thombre R, Dhar A and Anant
S: DNA methyltransferases: A novel target for prevention and
therapy. Front Oncol. 4:802014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Glaser KB: HDAC inhibitors: Clinical
update and mechanism-based potential. Biochem Pharmacol.
74:659–671. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Humeniuk R, Mishra PJ, Bertino JR and
Banerjee D: Epigenetic reversal of acquired resistance to
5-fluorouracil treatment. Mol Cancer Ther. 8:1045–1054. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Keshelava N, Davicioni E, Wan Z, Ji L,
Sposto R, Triche TJ and Reynolds CP: Histone deacetylase 1 gene
expression and sensitization of multidrug-resistant neuroblastoma
cell lines to cytotoxic agents by depsipeptide. J Natl Cancer Inst.
99:1107–1119. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Thurn KT, Thomas S, Moore A and Munster
PN: Rational therapeutic combinations with histone deacetylase
inhibitors for the treatment of cancer. Future Oncol. 7:263–283.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Stiborová M, Eckschlager T, Poljaková J,
Hraběta J, Adam V, Kizek R and Frei E: The synergistic effects of
DNA-targeted chemotherapeutics and histone deacetylase inhibitors
as therapeutic strategies for cancer treatment. Curr Med Chem.
19:4218–4238. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ikehata M, Ogawa M, Yamada Y, Tanaka S,
Ueda K and Iwakawa S: Different effects of epigenetic modifiers on
the cytotoxicity induced by 5-fluorouracil, irinotecan or
oxaliplatin in colon cancer cells. Biol Pharm Bull. 37:67–73. 2014.
View Article : Google Scholar
|
|
18
|
Ueda H, Nakajima H, Hori Y, Fujita T,
Nishimura M, Goto T and Okuhara M: FR901228, a novel antitumor
bicyclic depsipeptide produced by Chromobacterium violaceum no. 968
I. Taxonomy, fermentation, isolation, physico-chemical and
biological properties, and antitumor activity. J Antibiot (Tokyo).
47:301–310. 1994. View Article : Google Scholar
|
|
19
|
Ueda H, Nakajima H, Hori Y, Goto T and
Okuhara M: Action of FR901228, a novel antitumor bicyclic
depsipeptide produced by Chromobacterium violaceum no. 968 on
Ha-ras transformed NIH3T3 cells. Biosci Biotechnol Biochem.
58:1579–1583. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Furumai R, Matsuyama A, Kobashi N, Lee KH,
Nishiyama M, Nakajima H, Tanaka A, Komatsu Y, Nishino N, Yoshida M,
et al: FK228 (depsipeptide) as a natural prodrug that inhibits
class I histone deacetylases. Cancer Res. 62:4916–4921.
2002.PubMed/NCBI
|
|
21
|
Lee JH, Park JH, Jung Y, Kim JH, Jong HS,
Kim TY and Bang YJ: Histone deacetylase inhibitor enhances
5-fluorouracil cytotoxicity by down-regulating thymidylate synthase
in human cancer cells. Mol Cancer Ther. 5:3085–3095. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tumber A, Collins LS, Petersen KD,
Thougaard A, Christiansen SJ, Dejligbjerg M, Jensen PB, Sehested M
and Ritchie JW: The histone deacetylase inhibitor PXD101 synergises
with 5-fluorouracil to inhibit colon cancer cell growth in vitro
and in vivo. Cancer Chemother Pharmacol. 60:275–283. 2007.
View Article : Google Scholar
|
|
23
|
Di Gennaro E, Bruzzese F, Pepe S, Leone A,
Delrio P, Subbarayan PR, Avallone A and Budillon A: Modulation of
thymidilate synthase and p53 expression by HDAC inhibitor
vorinostat resulted in synergistic antitumor effect in combination
with 5FU or raltitrexed. Cancer Biol Ther. 8:782–791. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fazzone W, Wilson PM, Labonte MJ, Lenz HJ
and Ladner RD: Histone deacetylase inhibitors suppress thymidylate
synthase gene expression and synergize with the fluoropyrimidines
in colon cancer cells. Int J Cancer. 125:463–473. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wolter F, Akoglu B, Clausnitzer A and
Stein J: Downregulation of the cyclin D1/Cdk4 complex occurs during
resveratrol-induced cell cycle arrest in colon cancer cell lines. J
Nutr. 131:2197–2203. 2001.PubMed/NCBI
|
|
26
|
Lowry OH, Rosebrough NJ, Farr AL and
Randall RJ: Protein measurement with the Folin phenol reagent. J
Biol Chem. 193:265–275. 1951.PubMed/NCBI
|
|
27
|
Mi H, Muruganujan A and Thomas PD: PANTHER
in 2013: Modeling the evolution of gene function, and other gene
attributes, in the context of phylogenetic trees. Nucleic Acids
Res. 41:D377–D386. 2013. View Article : Google Scholar :
|
|
28
|
Doi S, Soda H, Oka M, Tsurutani J,
Kitazaki T, Nakamura Y, Fukuda M, Yamada Y, Kamihira S and Kohno S:
The histone deacetylase inhibitor FR901228 induces
caspase-dependent apoptosis via the mitochondrial pathway in small
cell lung cancer cells. Mol Cancer Ther. 3:1397–1402.
2004.PubMed/NCBI
|
|
29
|
Fang L, Igarashi M, Leung J, Sugrue MM,
Lee SW and Aaronson SA: p21Waf1/Cip1/Sdi1 induces permanent growth
arrest with markers of replicative senescence in human tumor cells
lacking functional p53. Oncogene. 18:2789–2797. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Geller JI, Szekely-Szucs K, Petak I, Doyle
B and Houghton JA: P21Cip1 is a critical mediator of the cytotoxic
action of thymidylate synthase inhibitors in colorectal carcinoma
cells. Cancer Res. 64:6296–6303. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ting JP and Trowsdale J: Genetic control
of MHC class II expression. Cell. 109(Suppl): S21–S33. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gai X, Tu K, Li C, Lu Z, Roberts LR and
Zheng X: Histone acetyltransferase PCAF accelerates apoptosis by
repressing a GLI1/BCL2/BAX axis in hepatocellular carcinoma. Cell
Death Dis. 6:e17122015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Magner WJ, Kazim AL, Stewart C, Romano MA,
Catalano G, Grande C, Keiser N, Santaniello F and Tomasi TB:
Activation of MHC class I, II, and CD40 gene expression by histone
deacetylase inhibitors. J Immunol. 165:7017–7024. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Beresford GW and Boss JM: CIITA
coordinates multiple histone acetylation modifications at the
HLA-DRA promoter. Nat Immunol. 2:652–657. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Masternak K and Reith W: Promoter-specific
functions of CIITA and the MHC class II enhanceosome in
transcriptional activation. EMBO J. 21:1379–1388. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Niesen MI and Blanck G: Rescue of major
histocompatibility - DR surface expression in
retinoblastoma-defective, non-small cell lung carcinoma cells by
the MS-275 histone deacetylase inhibitor. Biol Pharm Bull.
32:480–482. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ma XC, Hattori T, Kushima R, Terata N and
Kodama M: Expression of HLA-class II antigen in gastric carcinomas.
Its relationship to histopathological grade, lymphocyte
infiltration and five-year survival rate. Acta Oncol. 33:187–190.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ishigami S, Aikou T, Natsugoe S, Hokita S,
Iwashige H, Tokushige M and Sonoda S: Prognostic value of HLA-DR
expression and dendritic cell infiltration in gastric cancer.
Oncology. 55:65–69. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
West AC, Smyth MJ and Johnstone RW: The
anticancer effects of HDAC inhibitors require the immune system.
OncoImmunology. 3:e274142014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Fehlker M, Huska MR, Jöns T,
Andrade-Navarro MA and Kemmner W: Concerted down-regulation of
immune-system related genes predicts metastasis in colorectal
carcinoma. BMC Cancer. 14:64–75. 2014. View Article : Google Scholar : PubMed/NCBI
|
